LEADER 04094nam 22006855 450 001 9910253931703321 005 20200629143259.0 010 $a3-319-46877-4 024 7 $a10.1007/978-3-319-46877-8 035 $a(CKB)3710000001151963 035 $a(DE-He213)978-3-319-46877-8 035 $a(MiAaPQ)EBC4838235 035 $a(PPN)200512757 035 $a(EXLCZ)993710000001151963 100 $a20170407d2017 u| 0 101 0 $aeng 135 $aurnn|008mamaa 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aNext Generation Antibody Drug Conjugates (ADCs) and Immunotoxins /$fedited by Ulf Grawunder, Stefan Barth 205 $a1st ed. 2017. 210 1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2017. 215 $a1 online resource (XI, 181 p. 57 illus., 39 illus. in color.) 225 1 $aMilestones in Drug Therapy,$x2296-6056 311 $a3-319-46875-8 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aChemical Assembly of Antibody-Drug Conjugates -- Pre-clinical evaluation of ADCs delivering highly potent pyrrolobenzodiazepine (PBD) dimers -- Stable and homogeneous drug conjugation by sequential bis-alkylation at disulfide bonds using bis-sulfone reagents -- Calicheamicin antibody-drug conjugates for liquid- and solid tumor indications -- Enzyme-based strategies to generate site-specifically conjugated Antibody Drug Conjugates -- Substance P ? Saporin for the Treatment of Intractable Pain -- Recombinant immunotoxins for Chronic Inflammatory Disease -- BL22: A milestone in targeting CD22. 330 $aThis book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of action and off target activities. The book introduces scientists to all of the prerequisites that must be properly addressed, including identification of the right target, specific traits of target binding antibodies, proper selection of the toxic payload, internalization induced by binding, and next generation conjugation and linker technologies. These knowledge-based, revolutionary new drug principles will form the cornerstone of the future standard of care and will lead to major advances in application, as well as improved quality of life and patient survival rates. This book will be of interest to biotech companies and researchers working in the fields of immunology, pharmacology, and oncology. 410 0$aMilestones in Drug Therapy,$x2296-6056 606 $aPharmacology 606 $aAntibodies 606 $aPharmacotherapy 606 $aCancer research 606 $aOncology   606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 606 $aAntibodies$3https://scigraph.springernature.com/ontologies/product-market-codes/B14010 606 $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 615 0$aPharmacology. 615 0$aAntibodies. 615 0$aPharmacotherapy. 615 0$aCancer research. 615 0$aOncology  . 615 14$aPharmacology/Toxicology. 615 24$aAntibodies. 615 24$aPharmacotherapy. 615 24$aCancer Research. 615 24$aOncology. 676 $a615.373 702 $aGrawunder$b Ulf$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aBarth$b Stefan$4edt$4http://id.loc.gov/vocabulary/relators/edt 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910253931703321 996 $aNext Generation Antibody Drug Conjugates (ADCs) and Immunotoxins$92233526 997 $aUNINA